Dr. Lal Pathlabs (LALPATHLAB) Share Price Falls 3.23% Today; What the Decline Signals

Dr. Lal Pathlabs Share Price fell to Rs 1,859.85 on 04 September 2026 at 9:35:51 AM IST, down Rs 62.05 or 3.23% from the previous close of Rs 1,921.90, taking the company’s market capitalisation to Rs 32,118.71 crore. The stock is drawing attention in today’s market update because the decline came early in the session, with the day’s open at Rs 1,915.55 and the price slipping to an intraday low of Rs 1,854.40.

The supplied data confirms the price fall, but it does not establish a company-specific catalyst behind today’s move. That matters because Dr. Lal Pathlabs Stock News is being driven by verified price action rather than any confirmed corporate trigger in the dataset. For investors tracking Dr. Lal Pathlabs Share Price Today, the important metrics now are the gap between the current price and recent trading levels, the company’s valuation multiples, and how its profitability compares with peers in the Healthcare sector. Univest views this as a data-led stock analysis event rather than a narrative-led one.

Dr. Lal Pathlabs (LALPATHLAB) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,859.85
Previous Close	Rs 1,921.9
Today's Move	-Rs 62.05 (-3.23%)
Open	Rs 1,915.55
High	Rs 1,915.55
Low	Rs 1,854.4
Turnover	Rs 0.56 crore
Market Capitalisation	Rs 32,118.71 crore
Market Cap Category	Large Cap

Dr. Lal Pathlabs Share Price Today reflects a clear same-day decline, with the stock falling from the previous close of Rs 1,921.90 to Rs 1,859.85. The share opened at Rs 1,915.55, which also stood as the day’s high, and later touched a low of Rs 1,854.40. That pattern suggests the stock faced pressure soon after the open and did not reclaim the opening zone in early trade. Turnover stood at Rs 0.56 crore at the time of the update.

As aLarge Capstock, Dr. Lal Pathlabs is being watched not only for the 3.23% decline but also for where the price sits relative to key reference levels. The current price is slightly below the 50-day moving average of Rs 1,915.11, while remaining comfortably above the 200-day moving average of Rs 1,600.57. The available RSI reading is 58.77, which points to broadly neutral to moderately firm momentum rather than an extremely weak setup. That makes the current Dr. Lal Pathlabs Share Price Fall more relevant to read alongside valuation and business quality metrics.

Dr. Lal Pathlabs (LALPATHLAB) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 32,118.71 crore
P/E Ratio	59.53x
P/B Ratio	12.35x
ROE	22.37%
ROCE	29.56%
EPS	Rs 32.29
Book Value Per Share	Rs 155.67
Dividend Yield	1.07%

Dr. Lal Pathlabs Fundamental Analysis shows a company that still carries strong profitability metrics despite today’s decline in the stock price. The company’s market cap stands at Rs 32,118.71 crore, and its valuation is built around a price-to-earnings ratio of 59.53 and a price-to-book ratio of 12.35. On profitability, return on equity is 22.37% and return on capital employed is 29.56%, both figures that indicate solid capital efficiency on the supplied numbers.

EPS stands at Rs 32.29, which represents earnings attributable to each share. Book value per share is Rs 155.67, offering the accounting net worth behind each share, while the dividend yield is 1.07, reflecting the historical payout relative to the current market price. Taken together, these numbers show why Dr. Lal Pathlabs Share Price continues to attract investor attention even on a weak day: the valuation is elevated, but the profitability base is also strong. Univest would read this mix as a balance between premium pricing and robust return ratios, which is why the stock remains important in Healthcare stock analysis.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Hospital & Healthcare Services
Benchmark Scope	same industry
Company P/E Ratio	59.53x
Benchmark Median P/E	47.1x
Benchmark Average P/E	101.08x
Benchmark P/E Range	7.93x to 1,534.08x
Company P/B Ratio	12.35x
Benchmark Median P/B	4.22x
Benchmark Average P/B	4.58x
Company ROE	22.37%
Benchmark Median ROE	12.88%
Benchmark Average ROE	14.16%
Company ROCE	29.56%
Benchmark Median ROCE	15.77%
Benchmark Average ROCE	3.29%
Company Market Capitalisation	Rs 32,118.71 crore
Benchmark Median Market Cap	Rs 559.19 crore
Benchmark Average Market Cap	Rs 11,593.37 crore

Dr. Lal Pathlabs operates within the Healthcare sector and the Hospital & Healthcare Services industry in the supplied classification, so the most useful comparison is against the same-industry benchmark of 64 companies. That benchmark shows how today’s share price decline sits within a much broader valuation and profitability framework.

On valuation, the company P/E of 59.53 is above the industry median of 47.10 but below the industry average of 101.08, with the benchmark range stretching from 7.93 to 1,534.08 across 57 companies. The company’s P/B of 12.35 is far above the industry median of 4.22 and average of 4.58, and still below the benchmark maximum of 15.40 across 64 companies. On profitability, ROE of 22.37% is comfortably above the industry median of 12.88% and average of 14.16. ROCE of 29.56% is also above the median of 15.77% and well above the benchmark average of 3.29 across 62 companies.

Size also matters in this comparison. Dr. Lal Pathlabs Market Cap of Rs 32,118.71 crore is far above the industry median market cap of Rs 559.19 crore and also above the average of Rs 11,593.37 crore, though below the largest company in the benchmark at Rs 1,25,308.33 crore. Univest therefore sees the stock as a sizeable, high-return player trading at a premium to much of its industry on book value and above-median earnings multiples.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Apollo Hospitals Enterprise	APOLLOHOSP	1,25,308.33	60.45	13.04	23.54	21.73
Max Healthcare Institute	MAXHEALTH	96,743.68	66.42	8.86	14.53	14.97
MANIPAL HEALTH ENTERPRI L	MANIPALHOS	93,279.97	107.02	5.23	12.95	13.93
Fortis Healthcare	FORTIS	68,991.85	65.75	6.78	11.32	14.07
Aster DM Healthcare	ASTERDM	66,430.16	215.24	13.81	9.32	11.46

Against major listed peers, Dr. Lal Pathlabs sits in an interesting middle ground on valuation and profitability. Its P/E of 59.53 is slightly below Apollo Hospitals at 60.45, below Max Healthcare at 66.42, Fortis at 65.75, Manipal Health at 107.02 and far below Aster DM Healthcare at 215.24. That means the company is not the cheapest in absolute terms, but it is also not the most aggressively valued among large Healthcare names in the comparison set.

On price-to-book, Dr. Lal Pathlabs at 12.35 trades close to Apollo Hospitals at 13.04 and Aster DM Healthcare at 13.81, while sitting above Max Healthcare at 8.86, Fortis at 6.78 and Manipal Health at 5.23. Profitability gives stronger support to the company’s premium positioning. ROE at 22.37% is above Max, Fortis, Manipal and Aster, and only modestly below Apollo’s 23.54%. ROCE at 29.56% is higher than Apollo’s 21.73%, Max’s 14.97%, Fortis’ 14.07%, Manipal’s 13.93% and Aster’s 11.46%. In market-cap terms, Dr. Lal Pathlabs at Rs 32,118.71 crore is smaller than Apollo, Max, Manipal, Fortis and Aster, but still substantial enough to remain a major sector stock to watch on Univest.

Why Investors Are Watching Dr. Lal Pathlabs

• The stock fell 3.23% today to Rs 1,859.85 from Rs 1,921.90.
• Intraday price action was weak, with the open at Rs 1,915.55 also marking the day’s high.
• The stock is trading just below the 50-day moving average of Rs 1,915.11 but above the 200-day moving average of Rs 1,600.57.
• Valuation remains rich at 59.53 times earnings and 12.35 times book value.
• Profitability is strong, with ROE of 22.37% and ROCE of 29.56% versus industry medians.

About Dr. Lal Pathlabs

In the supplied market classification, Dr. Lal Pathlabs is part of the Healthcare sector and the Hospital & Healthcare Services industry. Within that listed universe, the company stands out by market capitalisation at Rs 32,118.71 crore, placing it well above the industry median size. That makes Dr. Lal Pathlabs Share Price relevant not only as a daily stock move but also as a signal followed within a broader healthcare peer set tracked by investors and on Univest.

Track Dr. Lal Pathlabs Share Price on Univest

UseDr. Lal Pathlabs (LALPATHLAB) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

Investors tracking Dr. Lal Pathlabs Share Price can use Univest to follow live share price moves, key fundamental ratios, market capitalisation trends, shareholding pattern updates when available, 52-week levels and broader market insights. Univest also helps place Dr. Lal Pathlabs Stock News in context through sector benchmarks, peer comparison and price action tracking so users can monitor the stock with verified market data.

Frequently Asked Questions

Why is Dr. Lal Pathlabs Share Price falling today?

Ans. Dr. Lal Pathlabs Share Price is down 3.23% today at Rs 1,859.85 versus the previous close of Rs 1,921.90. The supplied data confirms the decline, but it does not identify any company-specific catalyst behind the move.

What is Dr. Lal Pathlabs Share Price Today?

Ans. Dr. Lal Pathlabs Share Price Today is Rs 1,859.85 as of 9:35:51 AM IST on 04 September 2026. The stock is lower by Rs 62.05, with the day’s trading range so far between Rs 1,854.40 and Rs 1,915.55.

How did the stock trade intraday?

Ans. The stock opened at Rs 1,915.55, which also remained the intraday high, and then slipped to Rs 1,854.40 before trading at Rs 1,859.85. This shows the selling pressure emerged early and the opening level was not regained.

Is Dr. Lal Pathlabs a large-cap stock?

Ans. Yes, the company is classified as a Large Cap stock in the supplied data. Its market capitalisation stands at Rs 32,118.71 crore, making it significantly larger than the industry median market cap of Rs 559.19 crore.

What do the valuation ratios indicate for Dr. Lal Pathlabs?

Ans. The stock trades at a P/E of 59.53 and a P/B of 12.35. That places it above the industry median P/E of 47.10 and well above the median P/B of 4.22, indicating premium valuation levels.

How profitable is Dr. Lal Pathlabs compared with its industry?

Ans. Dr. Lal Pathlabs reports ROE of 22.37% and ROCE of 29.56%. Both are above the same-industry medians of 12.88% and 15.77%, suggesting stronger profitability and capital efficiency than many listed peers in the benchmark.

How does Dr. Lal Pathlabs compare with major peers on P/E?

Ans. Its P/E of 59.53 is close to Apollo Hospitals at 60.45 and below Max Healthcare at 66.42, Fortis at 65.75, Manipal Health at 107.02 and Aster DM Healthcare at 215.24 in the supplied peer set.

What does EPS, book value and dividend yield show?

Ans. EPS stands at Rs 32.29, book value per share is Rs 155.67 and dividend yield is 1.07. Together, these figures show the stock’s earnings base, accounting net worth per share and historical payout profile.

What should investors monitor next in Dr. Lal Pathlabs Stock News?

Ans. Investors can monitor whether the stock stabilises near the day low of Rs 1,854.40 or reclaims the Rs 1,915.55 opening zone, while also tracking valuation, peer comparisons and future updates on Univest for broader context.